Scholarlink

Background <p>Craniopharyngiomas, rare primary brain tumors of the pituitary-hypothalamic axis, frequently result in sicubstantial morbidity, including compromised quality of life, vision impairment, hypothalamic and endocrine dysfunction, and neuroendocrine disturbances. Of particular importance is the development of hypothalamic obesity, which affects up to 25% of patients at diagnosis and increases to 50% after treatment. Genotyping has revealed that over 90% of papillary craniopharyngiomas (PCP) harbor BRAF V600E mutations. Recent studies have demonstrated a significant reduction in tumor size with the use of BRAF-MEK inhibitors in PCP.</p> Methods <p>We conducted a systematic review of recent literature on pretreatment or neo-adjuvant medical therapies, analyzing their effectiveness, safety, and sequelae following surgical treatment with this new approach.</p> Results <p>At the time of this review, 15 studies involving more than 50 patients have been published, with a response rate of up to 90%.</p> Conclusion <p>Based on this evidence, we propose a new treatment paradigm aimed at improving outcomes by maximizing relief from compressive symptoms while minimizing hypothalamic dysfunction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月10日

查看全文
  • Carlos González-Gallego,
  • Pedro Molina,
  • Cristina Hostalot,
  • Anna Oliva,
  • Alberto Blanco,
  • Paloma Puyalto de Pablo,
  • Silvia Comas,
  • Cristina Carrato,
  • Elena Valassi,
  • Manel Puig-Domingo

摘要

Background

Craniopharyngiomas, rare primary brain tumors of the pituitary-hypothalamic axis, frequently result in sicubstantial morbidity, including compromised quality of life, vision impairment, hypothalamic and endocrine dysfunction, and neuroendocrine disturbances. Of particular importance is the development of hypothalamic obesity, which affects up to 25% of patients at diagnosis and increases to 50% after treatment. Genotyping has revealed that over 90% of papillary craniopharyngiomas (PCP) harbor BRAF V600E mutations. Recent studies have demonstrated a significant reduction in tumor size with the use of BRAF-MEK inhibitors in PCP.

Methods

We conducted a systematic review of recent literature on pretreatment or neo-adjuvant medical therapies, analyzing their effectiveness, safety, and sequelae following surgical treatment with this new approach.

Results

At the time of this review, 15 studies involving more than 50 patients have been published, with a response rate of up to 90%.

Conclusion

Based on this evidence, we propose a new treatment paradigm aimed at improving outcomes by maximizing relief from compressive symptoms while minimizing hypothalamic dysfunction.